Evidence map›Paper›PMID 42171857›Full record

ArticleJournal of hematopathology2026

Myeloid/lymphoid neoplasm with FLT3 gene fusion: report of a case with a novel t(5;13)(q13;q12) SSBP2::FLT3 fusion.

James R Cook, Caroline Astbury, David S Bosler, John C Molina, Heesun J Rogers, Ronald M Sobecks, Anna B Owczarczyk

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

James R CookDepartment of Pathology and Laboratory Medicine, Diagnostics Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Caroline AstburyDepartment of Pathology and Laboratory Medicine, Diagnostics Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
David S BoslerDepartment of Pathology and Laboratory Medicine, Diagnostics Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
John C MolinaDepartment of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Heesun J RogersDepartment of Pathology and Laboratory Medicine, Diagnostics Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Ronald M SobecksDepartment of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA.
Anna B OwczarczykDepartment of Pathology and Laboratory Medicine, Diagnostics Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, USA. owczara@ccf.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (M/LN-eo-TK) are diverse, with most cases showing a combination of lymphoblastic leukemia/lymphoma and myeloproliferative features. Various tyrosine kinase fusion genes have been identified, including FLT3 fusions. RNA based next generation sequencing studies offer an effective approach to detect such pathogenic fusion genes, including the novel SSBP2::FLT3 fusion described here. Timely identification of this fusion gene led to targeted management of our patient, who achieved complete resolution of his FDG-avid lymphadenopathy only after the addition of gilteritinib. Two years after successful bone marrow transplant, the patient remains in complete remission. Clinicians and pathologists should have a low index of suspicion for a M/LN-eo-TK when evaluating patients with and without unexplained eosinophilia in the context of extramedullary lymphoid or myeloid disease or unusual myeloproliferative disorders.

Indexed as

Chromosomes, Human, Pair 5DNA-Binding Proteinsfms-Like Tyrosine Kinase 3Gene FusionMyeloproliferative DisordersOncogene Proteins, FusionTranslocation, GeneticHumansMaleDNA-Binding ProteinsFLT3 protein, humanfms-Like Tyrosine Kinase 3Oncogene Proteins, FusionFLT3 fusionMyeloid/lymphoid neoplasm with eosinophiliaRNA-NGS

Identifiers

PMID42171857
PMCPMC13197295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.